Xiaoyu Y. Lai

Hangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 99 publications

Pre-transplant Clostridioides difficile infection predicts subsequent gastrointestinal GVHD and non-relapse mortality after allogeneic hematopoietic stem cell transplantation.

Pre-transplant Clostridioides difficile infection predicts subsequent gastrointestinal GVHD and non-relapse mortality after allogeneic hematopoietic stem cell transplantation.

Journal: Cell transplantation

Published: June 13, 2026

Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial.

Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial.

Journal: The Lancet. Haematology

Published: March 20, 2026

Low-dose chidamide maintenance therapy following allogeneic hematopoietic cell transplantation in T-cell acute lymphoblastic leukemia or lymphomas: a phase II, open-label, multicenter, single-arm trial.

Low-dose chidamide maintenance therapy following allogeneic hematopoietic cell transplantation in T-cell acute lymphoblastic leukemia or lymphomas: a phase II, open-label, multicenter, single-arm trial.

Journal: The Lancet regional health. Western Pacific

Published: March 18, 2026

Peritransplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD-mutated acute myeloid leukemia.

Peritransplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD-mutated acute myeloid leukemia.

Journal: Blood advances

Published: February 27, 2026

Systemic treatment with the ROCK2 inhibitor belumosudil in ocular chronic graft versus host disease.

Systemic treatment with the ROCK2 inhibitor belumosudil in ocular chronic graft versus host disease.

Journal: American journal of ophthalmology

Published: February 24, 2026

Prognostic impact of clinico-genetic characteristics and donor types in NPM1-mutated AML undergoing allogeneic hematopoietic stem cell transplantation.

Prognostic impact of clinico-genetic characteristics and donor types in NPM1-mutated AML undergoing allogeneic hematopoietic stem cell transplantation.

Journal: Cell transplantation

Published: February 12, 2026

Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial.

Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial.

Journal: Cancer

Published: February 08, 2026

Peri-transplant TP53 molecular MRD as a prognostic biomarker of relapse in TP53-mutated AML/MDS undergoing allogeneic HCT.

Peri-transplant TP53 molecular MRD as a prognostic biomarker of relapse in TP53-mutated AML/MDS undergoing allogeneic HCT.

Journal: Blood cancer journal

Published: January 12, 2026

The safety and efficacy of belumosudil and ruxolitinib combination in ruxolitinib refractory cGVHD.

The safety and efficacy of belumosudil and ruxolitinib combination in ruxolitinib refractory cGVHD.

Journal: Bone marrow transplantation

Published: November 27, 2025

Salvage Therapy With Inotuzumab Ozogamicin in Relapsed/Refractory B-ALL After CAR-T Therapy and HSCT: A Case Series.

Salvage Therapy With Inotuzumab Ozogamicin in Relapsed/Refractory B-ALL After CAR-T Therapy and HSCT: A Case Series.

Journal: Cancer reports (Hoboken, N.J.)

Published: November 12, 2025

Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-Up.

Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-Up.

Journal: American journal of hematology

Published: September 17, 2025

Validation of risk stratification and novel prognostic biomarkers in asian adult HSCT recipients with TA-TMA: A multicenter real-world study.

Validation of risk stratification and novel prognostic biomarkers in asian adult HSCT recipients with TA-TMA: A multicenter real-world study.

Journal: Bone marrow transplantation

Published: September 01, 2025

Showing 1-12 of 99

Last Updated: 09/26/2026